GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beijing Tong Ren Tang Chinese Medicine Co Ltd (HKSE:03613) » Definitions » Operating Income

Beijing Tong Ren Tang Chinese Medicine Co (HKSE:03613) Operating Income : HK$639 Mil (TTM As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Beijing Tong Ren Tang Chinese Medicine Co Operating Income?

Beijing Tong Ren Tang Chinese Medicine Co's Operating Income for the six months ended in Dec. 2023 was HK$319 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was HK$639 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Beijing Tong Ren Tang Chinese Medicine Co's Operating Income for the six months ended in Dec. 2023 was HK$319 Mil. Beijing Tong Ren Tang Chinese Medicine Co's Revenue for the six months ended in Dec. 2023 was HK$712 Mil. Therefore, Beijing Tong Ren Tang Chinese Medicine Co's Operating Margin % for the quarter that ended in Dec. 2023 was 44.76%.

Warning Sign:

Beijing Tong Ren Tang Chinese Medicine Co Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -1.1%.

Beijing Tong Ren Tang Chinese Medicine Co's 5-Year average Growth Rate for Operating Margin % was -1.10% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Beijing Tong Ren Tang Chinese Medicine Co's annualized ROC % for the quarter that ended in Dec. 2023 was 33.63%. Beijing Tong Ren Tang Chinese Medicine Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 46.97%.


Beijing Tong Ren Tang Chinese Medicine Co Operating Income Historical Data

The historical data trend for Beijing Tong Ren Tang Chinese Medicine Co's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Tong Ren Tang Chinese Medicine Co Operating Income Chart

Beijing Tong Ren Tang Chinese Medicine Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 649.64 670.83 783.05 815.29 638.80

Beijing Tong Ren Tang Chinese Medicine Co Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 440.30 287.59 527.70 320.05 318.76

Beijing Tong Ren Tang Chinese Medicine Co Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$639 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing Tong Ren Tang Chinese Medicine Co  (HKSE:03613) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Beijing Tong Ren Tang Chinese Medicine Co's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=637.518 * ( 1 - 12.31% )/( (1473.743 + 1850.685)/ 2 )
=559.0395342/1662.214
=33.63 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4106.319 - 184.434 - ( 2448.142 - max(0, 282.884 - 3543.394+2448.142))
=1473.743

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4434.445 - 205.067 - ( 2378.693 - max(0, 329.918 - 3844.322+2378.693))
=1850.685

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Beijing Tong Ren Tang Chinese Medicine Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=674.262/( ( (427.115 + max(842.992, 0)) + (436.813 + max(1164.387, 0)) )/ 2 )
=674.262/( ( 1270.107 + 1601.2 )/ 2 )
=674.262/1435.6535
=46.97 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(474.75 + 562.994 + 36.179) - (184.434 + 0 + 46.497)
=842.992

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(395.244 + 1011.649 + 30.992) - (205.067 + 0 + 68.431)
=1164.387

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Beijing Tong Ren Tang Chinese Medicine Co's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=318.759/712.138
=44.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Beijing Tong Ren Tang Chinese Medicine Co Operating Income Related Terms

Thank you for viewing the detailed overview of Beijing Tong Ren Tang Chinese Medicine Co's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Tong Ren Tang Chinese Medicine Co (HKSE:03613) Business Description

Traded in Other Exchanges
Address
Convention Plaza, 1 Harbour Road, Room 1405-1409, Office Tower, Wanchai, Hong Kong, HKG
Beijing Tong Ren Tang Chinese Medicine Co Ltd is a pharmaceutical retailer that specializes in Chinese medicine operating in three segments; Hong Kong includes the sale of Chinese medicine products and healthcare products and the provision of Chinese medical consultation and treatments through retail and wholesale of Chinese medicine products and healthcare products, Mainland China (PRC, but excluding Hong Kong, Macao, and Taiwan) includes wholesale of healthcare products in Mainland China and the sole distributor of Tong Ren Tang branded products of Tong Ren Tang Technologies and Tong Ren Tang Ltd, and Overseas includes retail and wholesale of Chinese medicine products and healthcare products and provision of Chinese medical consultation and treatments.

Beijing Tong Ren Tang Chinese Medicine Co (HKSE:03613) Headlines

No Headlines